Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Jasper Therapeutics Inc JSPR

Healthcare Biotechnology
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk... see more

Recent & Breaking News (NDAQ:JSPR)

Jasper Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire November 13, 2024

Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire November 7, 2024

Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

GlobeNewswire October 24, 2024

Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria

GlobeNewswire October 23, 2024

Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

GlobeNewswire October 14, 2024

Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma

GlobeNewswire September 10, 2024

Jasper Therapeutics to Present at Present at Upcoming September Investor Conferences

GlobeNewswire September 4, 2024

Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire August 13, 2024

Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

GlobeNewswire June 19, 2024

Jasper Therapeutics to Present at the Oppenheimer Novel Targets in Immunology Summit

GlobeNewswire June 17, 2024

Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress

GlobeNewswire June 14, 2024

Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024

GlobeNewswire May 30, 2024

Jasper Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire May 29, 2024

Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments

GlobeNewswire May 14, 2024

Jasper Therapeutics Announces Briquilimab Development Program in Asthma

GlobeNewswire May 13, 2024

Jasper Therapeutics to Present at Upcoming Investor Conferences in May

GlobeNewswire May 7, 2024

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 2, 2024

Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire March 21, 2024

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria

GlobeNewswire March 19, 2024

New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia

GlobeNewswire March 15, 2024